FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Guinney, J
   Dienstmann, R
   Wang, X
   de Reynies, A
   Schlicker, A
   Soneson, C
   Marisa, L
   Roepman, P
   Nyamundanda, G
   Angelino, P
   Bot, BM
   Morris, JS
   Simon, IM
   Gerster, S
   Fessler, E
   Melo, FDE
   Missiaglia, E
   Ramay, H
   Barras, D
   Homicsko, K
   Maru, D
   Manyam, GC
   Broom, B
   Boige, V
   Perez-Villamil, B
   Laderas, T
   Salazar, R
   Gray, JW
   Hanahan, D
   Tabernero, J
   Bernards, R
   Friend, SH
   Laurent-Puig, P
   Medema, JP
   Sadanandam, A
   Wessels, L
   Delorenzi, M
   Kopetz, S
   Vermeulen, L
   Tejpar, S
AF Guinney, Justin
   Dienstmann, Rodrigo
   Wang, Xin
   de Reynies, Aurelien
   Schlicker, Andreas
   Soneson, Charlotte
   Marisa, Laetitia
   Roepman, Paul
   Nyamundanda, Gift
   Angelino, Paolo
   Bot, Brian M.
   Morris, Jeffrey S.
   Simon, Iris M.
   Gerster, Sarah
   Fessler, Evelyn
   Melo, Felipe De Sousa E.
   Missiaglia, Edoardo
   Ramay, Hena
   Barras, David
   Homicsko, Krisztian
   Maru, Dipen
   Manyam, Ganiraju C.
   Broom, Bradley
   Boige, Valerie
   Perez-Villamil, Beatriz
   Laderas, Ted
   Salazar, Ramon
   Gray, Joe W.
   Hanahan, Douglas
   Tabernero, Josep
   Bernards, Rene
   Friend, Stephen H.
   Laurent-Puig, Pierre
   Medema, Jan Paul
   Sadanandam, Anguraj
   Wessels, Lodewyk
   Delorenzi, Mauro
   Kopetz, Scott
   Vermeulen, Louis
   Tejpar, Sabine
TI The consensus molecular subtypes of colorectal cancer
SO NATURE MEDICINE
AB Colorectal cancer (CRC) is a frequently lethal disease with heterogeneous outcomes and drug responses. To resolve inconsistencies among the reported gene expression-based CRC classifications and facilitate clinical translation, we formed an international consortium dedicated to large-scale data sharing and analytics across expert groups. We show marked interconnectivity between six independent classification systems coalescing into four consensus molecular subtypes (CMSs) with distinguishing features: CMS1 (microsatellite instability immune, 14%), hypermutated, microsatellite unstable and strong immune activation; CMS2 (canonical, 37%), epithelial, marked WNT and MYC signaling activation; CMS3 (metabolic, 13%), epithelial and evident metabolic dysregulation; and CMS4 (mesenchymal, 23%), prominent transforming growth factor-beta activation, stromal invasion and angiogenesis. Samples with mixed features (13%) possibly represent a transition phenotype or intratumoral heterogeneity. We consider the CMS groups the most robust classification system currently available for CRC-with clear biological interpretability-and the basis for future clinical stratification and subtype-based targeted interventions.
RI de Reynies, Aurelien/Q-8640-2017; Perez-Villamil, Beatriz/AAB-3572-2019;
   Manyam, Ganiraju C/B-5890-2014; Tabernero, Josep/AAG-5026-2019; Soneson,
   Charlotte/J-6740-2019; Laurent-Puig, Pierre/K-3641-2019; laurent-puig,
   pierre/B-2226-2013; Figueroa, Angelica/K-1266-2014; Wang,
   Xin/A-1130-2012; Vermeulen, Louis/B-7488-2008; Manyam,
   Ganiraju/E-9150-2012; Kopetz, Scott/AAC-1387-2019; Miquel, Josep
   Maria/AAG-3508-2019
OI de Reynies, Aurelien/0000-0002-1328-5290; Perez-Villamil,
   Beatriz/0000-0002-6881-7442; Soneson, Charlotte/0000-0003-3833-2169;
   Laurent-Puig, Pierre/0000-0001-8475-5459; laurent-puig,
   pierre/0000-0001-8475-5459; Figueroa, Angelica/0000-0001-5530-5213;
   Vermeulen, Louis/0000-0002-6066-789X; Manyam,
   Ganiraju/0000-0001-6006-8961; Kopetz, Scott/0000-0001-9647-3416;
   Schlicker, Andreas/0000-0002-6588-7883; Laderas,
   Ted/0000-0002-6207-7068; Bernards, Rene/0000-0001-8677-3423; Bot,
   Brian/0000-0002-2412-6826; Homicsko, Krisztian/0000-0003-0912-6198;
   Sadanandam, Anguraj/0000-0001-8485-5150; Boige,
   Valerie/0000-0002-7817-4663; Wang, Xin/0000-0002-5122-2418; missiaglia,
   edoardo/0000-0001-9221-0117; Tabernero, Josep/0000-0002-2495-8139
SN 1078-8956
EI 1546-170X
PD NOV
PY 2015
VL 21
IS 11
BP 1350
EP 1356
DI 10.1038/nm.3967
UT WOS:000364621200021
PM 26457759
ER

EF